Search results for " TRIALS"

showing 10 items of 932 documents

Qualitätssicherung in einer epidemiologischen Kohortenstudie: Durchführung von on-site Monitoring in gynäkologischen Arztpraxen

2014

Quality assurance is required for all relevant instruments and procedures in epidemiological studies just like for clinical trials. The structure and complexity of the monitoring was developed based on the monitoring in clinical trials and applied to an epidemiological cohort study on early detection of cervical cancer (MARZY Study). Analyses of the on-site monitoring in participating gynaecological practices during the baseline investigation of the MARZY cohort were presented. The baseline investigation of the MARZY study was conducted between 2005 and 2007 in the city of Mainz, the rural district of Mainz-Bingen and surrounding areas. Women, who were randomly selected via population regis…

Cervical cancermedicine.medical_specialtyeducation.field_of_studybusiness.industryHealth PolicyPopulationMedicine (miscellaneous)medicine.diseaseEducationClinical trialMonitoring in clinical trialsInformed consentFamily medicineEpidemiologyCohortmedicineeducationbusinessCohort studyZeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
researchProduct

The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of chronic venous disease.

2017

Despite continuous improvement in our knowledge and management of chronic venous disease (CVD), certain areas, such as the role of muscarinic receptors in the pathology and treatment of CVD, remain unexplored. The symposium "The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of CVD", held at the Annual Meeting of the European Venous Forum on 7-9 July 2016 in London, presented an update on the pathophysiology of CVD and highlighted how the combination of Ruscus extract, hesperidin methyl chalcone, and vitamin C (Ruscus/HMC/VitC; Cyclo 3® Fort), may counteract the deleterious processes underlying CVD. The data presented during this symposium are reported …

ChalconeInflammationAscorbic Acid030204 cardiovascular system & hematologyPharmacologyVeins03 medical and health scienceschemistry.chemical_compoundHesperidin0302 clinical medicineChalconesLondonMedicineHumansVascular DiseasesRandomized Controlled Trials as TopicbiologyVitamin Cbusiness.industryPlant ExtractsHesperidinCongresses as Topicbiology.organism_classificationResponse to treatmentPathophysiologyRuscusTreatment OutcomechemistryRuscus030220 oncology & carcinogenesisChronic DiseaseDrug Therapy Combinationmedicine.symptomCardiology and Cardiovascular MedicineVenous diseasebusinessPhytotherapyInternational angiology : a journal of the International Union of Angiology
researchProduct

High-flow nasal therapy versus noninvasive ventilation in COPD patients with mild-to-moderate hypercapnic acute respiratory failure: study protocol f…

2019

Background Noninvasive ventilation (NIV) is indicated to treat respiratory acidosis due to exacerbation of chronic obstructive pulmonary disease (COPD). Recent nonrandomized studies also demonstrated some physiological effects of high-flow nasal therapy (HFNT) in COPD patients. We designed a prospective, unblinded, multicenter, randomized controlled trial to assess the noninferiority of HFNT compared to NIV with respect to the reduction of arterial partial pressure of carbon dioxide (PaCO2) in patients with hypercapnic acute respiratory failure with mild-to-moderate respiratory acidosis. Methods We will enroll adult patients with acute hypercapnic respiratory failure, as defined by arterial…

Chronic ObstructiveTime FactorsExacerbationRespiratory ratemedicine.medical_treatmentMedicine (miscellaneous)Equivalence Trials as TopicAcute respiratory failurelaw.inventionPulmonary DiseaseHypercapnia03 medical and health sciencesPulmonary Disease Chronic ObstructiveStudy Protocol0302 clinical medicineAcute respiratory failure; Carbon dioxide; Chronic obstructive pulmonary disease; Emergency department; High-flow oxygen therapy through nasal cannula; Intensive care unit; Noninvasive ventilation; Acute Disease; Equivalence Trials as Topic; Humans; Hypercapnia; Italy; Lung; Multicenter Studies as Topic; Oxygen Inhalation Therapy; Prospective Studies; Pulmonary Disease Chronic Obstructive; Respiratory Insufficiency; Time Factors; Treatment Outcome; Noninvasive VentilationRandomized controlled triallawHigh-flow oxygen therapy through nasal cannulamedicineHumansMulticenter Studies as TopicPharmacology (medical)Intensive care unit030212 general & internal medicineProspective StudiesLungTidal volumeMechanical ventilationCOPDlcsh:R5-920business.industryEmergency departmentChronic obstructive pulmonary diseaseOxygen Inhalation Therapymedicine.diseaseIntensive care unitRespiratory acidosisTreatment OutcomeItalyCarbon dioxideAnesthesiaAcute DiseasebusinessRespiratory Insufficiencylcsh:Medicine (General)Acute respiratory failure; Carbon dioxide; Chronic obstructive pulmonary disease; Emergency department; High-flow oxygen therapy through nasal cannula; Intensive care unit; Noninvasive ventilationNoninvasive ventilation030217 neurology & neurosurgeryTrials
researchProduct

Finding the right dose of fulvestrant in breast cancer

2012

Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent.

Clinical Trials as TopicAntineoplastic Agents HormonalDose-Response Relationship DrugEstradiolFulvestrantbusiness.industryAntagonistEstrogen receptorBreast NeoplasmsGeneral MedicinePharmacologymedicine.diseaseEffective dose (pharmacology)Clinical trialSecond lineBreast cancerOncologymedicineHumansFemaleRadiology Nuclear Medicine and imagingbusinessFulvestrantmedicine.drugHormoneCancer Treatment Reviews
researchProduct

Changing paradigm in mild traumatic brain injury research

2016

Traumatic brain injury (TBI) is a major cause of death and disability among young adults. Recent data show that TBI affects about 1.7 million people annually in the United States (Faul and Coronado, 2015). After TBI, the primary injury produces almost irreparable brain damage. However, recent experimental studies have shown evidence for dynamic brain repair following TBI because endogenous progenitor cells may play regenerative roles in response to injuries (McGinn and Povlishock, 2015). In surviving patients, what plays a critical role in the clinical prognosis is the subsequent secondary injury; without effective treat- ment, cascades that include glutamatergic excitotoxicity and calcium …

Clinical Trials as TopicBiomedical ResearchNeural Stem CellsSettore MED/27 - NeurochirurgiaCell MembraneAnimalsHumansBrain ConcussionTrigeminal neuralgiaChronic Traumatic Encephalopathy
researchProduct

Improving transparency of scientific reporting to increase value and reduce waste in mental health research.

2015

Clinical Trials as TopicBiomedical Researchbusiness.industryMental DisordersGeneral MedicinePublic relationsEnvironmental economicsMental healthTransparency (behavior)030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineResearch DesignMedicineHumans030212 general & internal medicinebusinessScientific reportingRevista de psiquiatria y salud mental
researchProduct

Interleukins

1994

With interleukins (IL), a new class of potential drugs has been introduced into clinical research. These signal peptides are involved in the regulation of many physiological and pathophysiological processes. IL-1, -2, -3, -4, -6 and -11 have been tested in clinical trials. The growth promoting, growth inhibiting or immunomodulatory activities of interleukins represent the theoretical basis for large scale clinical testing, predominantly in malignant disease. Dose-dependent effects on numbers of peripheral blood cells and recovery from bone marrow failure have been demonstrated for IL-1, -3, -6 and -11. Phase III trials are in progress to determine their value for clinical practice. However,…

Clinical Trials as TopicClinical pharmacologybusiness.industryInterleukinsMelanomamedicine.medical_treatmentBone marrow failuremedicine.diseaseBioinformaticslaw.inventionClinical trialHaematopoiesisClinical researchCytokineAdjuvants ImmunologiclawRenal cell carcinomaNeoplasmsImmunologyAnimalsHumansMedicinePharmacology (medical)businessDrugs
researchProduct

Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use

2015

During the past decade, a large number of cell-based medicinal products have been tested in clinical trials for the treatment of various diseases and tissue defects. However, licensed products and those approaching marketing authorization are still few. One major area of challenge is the manufacturing and quality development of these complex products, for which significant manipulation of cells might be required. While the paradigms of quality, safety and efficacy must apply also to these innovative products, their demonstration may be demanding. Demonstration of comparability between production processes and batches may be difficult for cell-based medicinal products. Thus, the development …

Clinical Trials as TopicEmbryologyComputer scienceManufacturing processStem Cellsmedia_common.quotation_subjectControl (management)CommerceBiomedical EngineeringMarketing authorizationSocial Control FormalQuality developmentProduct (business)Risk analysis (engineering)HumansQuality (business)European UnionStem Cell Transplantationmedia_commonCell basedRegenerative Medicine
researchProduct

The use of Endurant stent-graft for abdominal aortic aneurysm: the story about extension of instruction for use with persistent good results of stent…

2012

The Endurant stent-graft (Medtronic, Inc., Minneapolis, MN, USA) is a latest generation device for the treatment of abdominal aortic aneurysm. The idea behind designing such a graft came from the intention to broad the instruction for use (IFU) and to enable it to treat more challenging anatomy including the 10mm neck lengths, and more severe suprarenal and infrarenal angulations. Endurant stent-graft has active fixation through suprarenal stent with anchoring pins to provide migration resistance, optimized heights of stents and spacing between them for improved flexibility and conformability, low-profile delivery system with hydrophilic coating and controlled simple deployment mechanism. S…

Clinical Trials as TopicEvidence-Based Medicine10042 Clinic for Diagnostic and Interventional RadiologyEndovascular Procedures610 Medicine & healthProsthesis DesignRisk Assessment2705 Cardiology and Cardiovascular Medicine10020 Clinic for Cardiac Surgery2746 SurgeryBlood Vessel ProsthesisBlood Vessel Prosthesis ImplantationTreatment OutcomeRisk FactorsHumansStentsClinical CompetenceRegistriesLearning Curvestents endovascular procedures aortic aneurysm abdominalAortic Aneurysm Abdominal
researchProduct

The protection of the person in medical research in the Spanish law.

2002

AbstractNo Abstract

Clinical Trials as TopicInformed ConsentHuman RightsHealth PolicyLiability LegalMedical researchFetal ResearchVulnerable PopulationsMinorsEmbryo ResearchHuman ExperimentationSpainLawPolitical scienceHumansHealth lawDisabled PersonsLawConfidentialityEthics Committees ResearchEuropean journal of health law
researchProduct